MDxHealth S.A.
NASDAQ:MDXHMedical - Diagnostics & Research
-$0.03 today
- Market cap
- $57.59M
- Beta
- 0.38
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$0.58
Volume 0.65M
Average 4.27M
Income Statement
Follow revenue through to earnings.
Revenue
$107.88M
FY 2025 · Annual
+19.8% YoYOperating Income
-$15.40M
FY 2025 · Annual
Net Income
-$33.52M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 22.24M | 37.05M | 70.19M | 90.05M | 107.88M |
| Cost of Revenue | 11.68M | 17.84M | 26.26M | 34.91M | 43.43M |
| Gross Profit | 10.56M | 19.22M | 43.93M | 55.14M | 64.44M |
| Gross Margin | 47.5% | 51.9% | 62.6% | 61.2% | 59.7% |
| Research & Development | 5.59M | 7.56M | 6.38M | 10.55M | 10.35M |
| Selling, General & Admin | 30.22M | 50.12M | 59.93M | 61.4M | 66.75M |
| Operating Expenses | 37.41M | 57.12M | 71.26M | 79.86M | 79.84M |
| Depreciation & Amortization | 3.04M | 4.91M | 6.86M | 8.04M | 9.21M |
| EBITDA | (24.09M) | (36.39M) | (30.47M) | (22.02M) | (14.01M) |
| EBITDA Margin | -108.3% | -98.2% | -43.4% | -24.5% | -13.0% |
| Operating Income | (26.84M) | (37.9M) | (27.33M) | (24.72M) | (15.4M) |
| Operating Margin | -120.7% | -102.3% | -38.9% | -27.5% | -14.3% |
| Interest Income | 11K | 125K | 1.09M | 1.08M | 1.5M |
| Interest Expense | 1.88M | 2.74M | 5.77M | 7.63M | 12.16M |
| Other Income / Expenses | (2.16M) | (6.14M) | (15.77M) | (12.97M) | (19.98M) |
| Income Before Tax | (29M) | (44.04M) | (43.1M) | (37.69M) | (35.38M) |
| Pre-Tax Margin | -130.4% | -118.9% | -61.4% | -41.9% | -32.8% |
| Income Tax Expense | 0 | 0 | 1K | 382K | (1.86M) |
| Net Income | (29M) | (44.04M) | (43.1M) | (38.07M) | (33.52M) |
| Net Margin | -130.4% | -118.9% | -61.4% | -42.3% | -31.1% |
| EPS (Basic) | (2.38) | (2.78) | (1.66) | (0.78) | (0.67) |
| EPS (Diluted) | (2.38) | (2.78) | (1.66) | (1.16) | (0.67) |
| 12.19M | 15.87M | 25.91M | 48.67M | 50.03M | |
| 12.19M | 15.87M | 25.91M | 48.67M | 50.03M |
MDXH Earnings Waterfall · TTM
NASDAQ:MDXH · Revenue to Net Income
Key Ratios
Analysis
$156.5M of revenue converted into -$55.7M of net income for the selected period. Gross margin is 61.8% and net margin is -35.5%, showing how much revenue survives after costs and taxes. EPS is $-1.27, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13D/A | SC 13D/A filing | Oct 15, 2026 | |
| 144 | Notice of proposed sale of securities | Sep 17, 2026 | |
| 6-K | 6-K filing | Sep 3, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 17, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 17, 2026 |
How much revenue does MDXH generate?
MDxHealth S.A. (MDXH) reported $107.88M of revenue in fiscal 2025.
Is MDXH profitable?
MDxHealth S.A. (MDXH) reported -$33.52M of net income, with a net margin of -31.1%.
Continue the stock analysis
Jump to another research area for this company.